Biogen Idec

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Biogen Idec
TickerBIIB
CIK #0000875045
CUSIP09062X103
SectorLife Sciences
IndustryBiological Products, (No Disgnostic Substances)
Phone6176792000
Address14 Cambridge Center
Cambridge, MA 02142
Source [EDGAR]
Market Cap, 13F ($BB)
1008060402002011201320152018
Business

Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Our core growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS); movement disorders, including Parkinson's disease; and ophthalmology. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of immunology; neurocognitive disorders; acute neurology; and pain. In addition, we commercialize biosimilars of advanced biologics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.

Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to our consolidated financial statements included in this report.

For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We also introduced the first approved treatment for SMA and are continuing to pursue research and development for potential advancements in the treatment of SMA, including a muscle enhancement program, novel antisense oligonucleotide (ASO) drug candidates and an oral splicing modulator. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, ALS, Parkinson's disease, choroideremia (CHM), X-linked retinitis pigmentosa (XLRP), systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), cognitive impairment associated with schizophrenia (CIAS), stroke, epilepsy and pain.

CIK Filing 2011 - 2021
[0000875045] 10-K
[0000875045] 10-Q
[0000875045] 3
[0000875045] 4
[0000875045] 5
[0000875045] 8-K
[0000875045] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Biogen Inc Denali Therapeutics Inc [2020-09-28] 11.16
Biogen Inc Sangamo Therapeutics Inc [2020-04-17] 17.37
Biogen Inc Nightstar Therapeutics PLC [2019-03-14] 61.6
Biogen Inc Solid Biosciences Inc [2019-02-14] 5.0
Biogen Inc Ionis Pharmaceuticals Inc [2018-06-07] 8.39
Biogen Inc Applied Genetic Technologies Corp [2015-08-20] 8.1
Price T Rowe Associates Inc /MD/ Biogen IDEC Inc [2015-02-12] 5.1
Vanguard Group Inc Biogen IDEC Inc [2015-02-11] 5.39
Vanguard Chester Funds Biogen IDEC Inc [2013-01-30] 5.05
FMR LLC Biogen IDEC Inc [2012-02-14] 0.0
Form 3/4/5 Filer 2011-2021
Kramer Robin
Guindo Chirfi
Vounatsos Michel
Sandrock Alfred
Biogen Ma Inc
Denali Therapeutics Inc
McDonnell Michael R
Gregory Ginger
Denner Alexander J
Papadopoulos Stelios
Pangia Robert W
Mulligan Richard
Mantas Jesus B
Leaming Nancy
Hawkins William A
Dorsa Caroline
Sherwin Stephen A
Rowinsky Eric K
Posner Brian S
Sangamo Therapeutics Inc
Galdes Alphonse
Alexander Susan H
Karp Daniel
Capello Jeffrey D
Schenk Lynn
Ehlers Michael D
McKenzie Paul
Covino Gregory F
Kress Jean-Paul
Clancy Paul J
Dipietro Kenneth
Karaboutis Adriana
Bioverativ Inc
Scangos George A
Koppel Adam
Artavanis-Tsakonas Spyridon
Cox John
Holtzman Steven H
Williams Douglas E
Kingsley Stuart A
Young William
Pawlicki Raymond
Gagnon Robert E
Granata Francesco
MM Shares Owned of 201.5 MM Total
Firm Period DFND Voting Shares
PRIMECAP Management Co/Ca/ [2020-09-30] SOLE 15.3 15.7
BlackRock Inc. [2020-09-30] SOLE 12.4 14.5
Vanguard Group Inc [2020-09-30] SOLE 0.0 11.6
State Street Corp [2020-09-30] DFND 6.3 7.5
Wellington Management Group LLP [2020-09-30] DFND 0.0 4.9
Clearbridge Investments LLC [2020-09-30] SOLE 3.9 4.0
Renaissance Technologies LLC [2020-09-30] SOLE 3.8 3.8
Susquehanna International Group LLP [2020-09-30] DFND 0.4 3.1
Geode Capital Management LLC [2020-09-30] DFND 2.9 2.9
Northern Trust Corp [2020-09-30] DFND 1.0 2.3
Bank of New York Mellon Corp [2020-09-30] DFND 2.0 2.3
AQR Capital Management LLC [2020-09-30] DFND 1.2 2.2
JPMorgan Chase & Co [2020-09-30] DFND 1.8 2.1
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 0.4 1.4
Citadel Advisors LLC [2020-09-30] DFND 1.3 1.3
Legal & General Group Plc [2020-09-30] DFND 0.9 1.3
Deutsche Bank AG [2020-09-30] DFND 0.9 1.2
FMR LLC [2020-09-30] DFND 0.0 1.1
Dimensional Fund Advisors LP [2020-09-30] DFND 1.0 1.1
American Century Companies Inc [2020-09-30] DFND 0.9 1.1
LSV Asset Management [2020-09-30] SOLE 0.7 1.0
PEAK6 Investments LLC [2020-09-30] DFND 0.9 0.9
Goldman Sachs Group Inc [2020-09-30] DFND 0.8 0.9
Bank of America Corp /DE/ [2020-09-30] DFND 0.1 0.9
Pictet Asset Management Ltd [2020-09-30] DFND 0.0 0.9
Invesco Ltd. [2020-09-30] DFND 0.0 0.9
van Eck Associates Corp [2020-09-30] SOLE 0.8 0.8
Wells Fargo & Co/Mn [2020-09-30] DFND 0.6 0.8
UBS Global Asset Management Americas Inc [2020-09-30] SOLE 0.5 0.7
Schwab Charles Investment Management Inc [2020-09-30] SOLE 0.7 0.7
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com